An anti-inflammatory diet as treatment for inflammatory bowel disease: a case series report.
An anti-inflammatory diet as treatment for inflammatory bowel disease: a case series report.
复制标题
抗炎饮食作为炎症性肠病的治疗方法：病例系列报告。
DOI：
10.1186/1475-2891-13-5
复制
发表时间：
2014-01-16
影响因子：
5.4
通讯作者：
Cave D
中科院分区：
文献类型：
--
作者：
Olendzki BC;Silverstein TD;Persuitte GM;Ma Y;Baldwin KR;Cave D
抗炎饮食（IBD-AID）是一种针对炎症性肠病（IBD）的营养方案，限制某些碳水化合物的摄入，包括摄入益生菌前和益生菌食物，并改变膳食脂肪酸，以证明IBD治疗的辅助饮食疗法的潜力。40例IBD患者连续提供IBD-AID，以帮助治疗他们的疾病，并进行回顾性分析。对其中11名患者的医疗记录进行了进一步审查，以确定饮食前后Harvey Bradshaw指数（HBI）或改良Truelove和Witts严重程度指数（MTLWSI）的变化。在40名IBD患者中，13名患者选择不尝试饮食（33%）。24例患者在达到依从性后反应良好或非常好（60%），3例患者的结果混合（7%）。在接受进一步病历审查的11名成人患者中，8名患有CD，3名患有UC，年龄范围为19-70岁，他们遵循饮食4周或更长时间。在IBD-AID之后，所有（100%）患者能够停止至少一种先前的IBD药物，并且所有患者的症状减轻，包括排便频率。平均基线HBI为11（范围1-20），平均随访评分为1.5（范围0-3）。平均基线MTLWSI为7（范围6-8），平均随访评分为0。HBI平均下降9.5，MTLWSI平均下降7。该病例系列表明IBD-AID作为治疗IBD的辅助饮食疗法的潜力。需要进行随机临床试验。
The Anti-Inflammatory Diet (IBD-AID) is a nutritional regimen for inflammatory bowel disease (IBD) that restricts the intake of certain carbohydrates, includes the ingestion of pre- and probiotic foods, and modifies dietary fatty acids to demonstrate the potential of an adjunct dietary therapy for the treatment of IBD. Forty patients with IBD were consecutively offered the IBD-AID to help treat their disease, and were retrospectively reviewed. Medical records of 11 of those patients underwent further review to determine changes in the Harvey Bradshaw Index (HBI) or Modified Truelove and Witts Severity Index (MTLWSI), before and after the diet. Of the 40 patients with IBD, 13 patients chose not to attempt the diet (33%). Twenty-four patients had either a good or very good response after reaching compliance (60%), and 3 patients’ results were mixed (7%). Of those 11 adult patients who underwent further medical record review, 8 with CD, and 3 with UC, the age range was 19–70 years, and they followed the diet for 4 or more weeks. After following the IBD-AID, all (100%) patients were able to discontinue at least one of their prior IBD medications, and all patients had symptom reduction including bowel frequency. The mean baseline HBI was 11 (range 1–20), and the mean follow-up score was 1.5 (range 0–3). The mean baseline MTLWSI was 7 (range 6–8), and the mean follow-up score was 0. The average decrease in the HBI was 9.5 and the average decrease in the MTLWSI was 7. This case series indicates potential for the IBD-AID as an adjunct dietary therapy for the treatment of IBD. A randomized clinical trial is warranted.
登录
查看更多内容
影响因子：
3.1
作者：
Cohen, Aaron B.;Lee, Dale;Long, Millie D.;Kappelman, Michael D.;Martin, Christopher F.;Sandler, Robert S.;Lewis, James D.
通讯作者：
Lewis, James D.
影响因子：
9.6
作者：
Hahnloser, D.;Pemberton, J. H.;Dozois, R. R.
通讯作者：
Dozois, R. R.
影响因子：
24.5
作者：
Comino, Isabel;Real, Ana;Sousa, Carolina
通讯作者：
Sousa, Carolina
影响因子：
4.4
作者：
Fujimori, Shunji;Gudis, Katya;Sakamoto, Choitsu
通讯作者：
Sakamoto, Choitsu
影响因子：
4.3
作者：
Day, Andrew S.;Ledder, Oren;Lemberg, Daniel A.
通讯作者：
Lemberg, Daniel A.